


New study uncovers potential therapeutic target for breast cancer

June 12 2023



Overexpression of full-length VIRMA enhances tumor development in vivo. **A** Tumor size measured over a period of 39 days in MDA-MB-231 xenografts overexpressing two different isoforms of VIRMA and eGFP alone ($n = 10$ per group). **B** Tumors collected at endpoint for each experimental group. **C** Measurement of the size and **D** weight of the tumors harvested at endpoint. **E** Representative images showing immunohistochemistry analysis of tumors from xenografts **B** obtained at the experiment endpoint. H&E, hematoxylin and eosin. Scale bars represent 50 μm. **F** Percentage Ki67 positive cells normalized to DAPI in tumors overexpressing the two isoforms of VIRMA and eGFP control ($n = 10$ fields from three tumors per group). **G** Number of CD31 positive vessels per field ($n \geq 12$ fields from three tumors per group). In **C**, **D**, **F** and **G**, statistical significance was determined using one-way ANOVA. Multiple comparisons of

the means were performed using the Tukey's test. Data are from ≥ 3 biological replicates and show mean \pm SD. *, *P*

Citation: New study uncovers potential therapeutic target for breast cancer (2023, June 12)
retrieved 2 May 2024 from

<https://medicalxpress.com/news/2023-06-uncovers-potential-therapeutic-breast-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.